통증 완화 패치 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pain relief patches market size is projected to expand from USD 4.85 billion in 2025 and USD 5.13 billion in 2026 to USD 6.76 billion by 2031, registering a CAGR of 5.69% between 2026 to 2031.

This report is Segmented by Product Type (Opioid Patches, Non-Opioid Patches), Application (Chronic Pain, Acute Pain, and More), Distribution Channel (Hospital Pharmacies, and More), End User (Hospitals, Home-Care Settings, Clinics & Rehabilitation Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Pain Relief Patches Market Trends and Insights

Accelerated OTC Adoption in Retail & E-Commerce Channels

Over-the-counter transdermal products are increasingly moving from pharmacy shelves to digital marketplaces, streamlining the purchasing process and enabling larger unit sizes that improve cost efficiency for frequent users. Hisamitsu has introduced bulk-format e-commerce options designed to fit standard mailboxes, enhancing convenience for chronic users while reducing delivery-related emissions. The shift to online channels is also expanding access to specialty formats, as seen with Sonoma Pharmaceuticals' launch of a burn-relief hydrogel patch in major U.S. retail chains. Larger pack sizes in e-commerce provide manufacturers with greater pricing flexibility and support subscription models that encourage adherence for long-term conditions. Updated U.S. quality standards for transdermal systems emphasize adhesion and dose consistency, favoring established players while supporting OTC market growth. These factors collectively strengthen the role of e-commerce and national retail in the pain relief patches market, driven by consumer demand for speed, convenience, and trusted brands.

Aging Population Driving Chronic Pain Prevalence

The aging global population is driving demand for localized, sustained pain relief solutions that minimize systemic exposure. By 2030, one-sixth of the global population is expected to be 60 or older, correlating with a rise in chronic musculoskeletal conditions requiring long-term pain management.In the U.S., chronic pain affects nearly a quarter of adults, with higher prevalence among older age groups. Guidelines caution against certain oral medications for seniors, increasing reliance on topical formulations like lidocaine, diclofenac, and capsaicin. Studies highlight the persistence of pain in older adults, emphasizing the need for personalized and multimodal approaches, including transdermal options. These trends sustain demand for pain relief patches as healthcare providers prioritize consistent treatment outcomes and reduced medication risks for aging patients.

Skin-Irritation & Adhesion Failures

Dermal reactions and adhesion issues are key factors driving product discontinuation, with recalls underscoring the consequences of inadequate adhesion or release performance in practical use. In early 2025, specific fentanyl transdermal lots were recalled due to adhesion failures, which posed risks of residual drug exposure to caregivers and household members. Compliance issues identified in late 2024 highlighted the critical need for stringent adhesion testing protocols and batch-release controls for topical analgesics. Reports of adverse events, such as local skin reactions and contact dermatitis from OTC lidocaine products, have intensified the focus on hypoallergenic adhesives and consistent adhesion across various skin types. Manufacturers are increasingly adopting silicone- and hydrocolloid-based adhesive systems to balance tack and breathability, reducing irritation risks. Enhanced market surveillance and updated labeling practices aim to minimize discontinuities and recalls, supporting growth in the pain relief patches market.

Other drivers and restraints analyzed in the detailed report include:

1. Regulatory Push Away from Systemic Opioids
2. Technological Advances in Drug-in-Adhesive & Microneedle Patches
3. Stringent FDA / EMA Clinical-Trial Cost & Timeline

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, non-opioid patches captured 62.34% of the pain relief patches market, with an expected CAGR of 8.10% through 2031, driven by a shift from opioid-based treatments for chronic non-cancer pain. The market is supported by labeling changes and safety advisories encouraging non-opioid options, particularly for older patients with polypharmacy and comorbidities. Manufacturers are innovating drug-in-adhesive platforms to deliver thin, comfortable patches with consistent release over 12-to-24-hour windows, enhancing adherence and reducing the need for rescue medication. The industry is expanding non-opioid formulations and sizes to cater to diverse needs, supported by flexible packaging and long-wear designs that improve therapy persistence.

Chronic pain applications accounted for 44.23% of the market in 2025, driven by sustained-release delivery that stabilizes symptoms in conditions like osteoarthritis, lower back pain, and neuropathy. Clinical guidelines favor topical solutions for older adults, reducing risks associated with oral medications. Long-wear patches that enable daily activities while minimizing oral dosing are in demand, supported by improved adhesion and comfort in non-opioid designs, ensuring consistent relief and reducing variability.

Sports-related pain is the fastest-growing segment, with a projected CAGR of 7.60% through 2031, fueled by self-care trends, online availability, and localized delivery benefits during training or recovery. Patches applied directly to muscles or joints allow activity without frequent dosing interruptions. OTC formats with menthol, methyl salicylate, or lidocaine maintain strong retail presence, supported by subscription and multi-pack offers catering to training schedules, sustaining growth in this segment.

Geography Analysis

In 2025, North America captured 39.67% of the pain relief patches market share, while Asia-Pacific emerged as the fastest-growing region with an 8.50% CAGR projected through 2031. In the United States, updated opioid patch labeling in 2025 encouraged a shift toward topical non-opioid analgesics for chronic non-cancer pain. The high prevalence of chronic pain among U.S. adults drives demand for long-wear patches that support daily functionality. Specialty patches remain critical for oncology and palliative care, addressing cases requiring consistent and strong analgesia.

In Europe, the pain relief patches market reflects stringent benefit-risk management by regulators and a growing focus on sustainable packaging and materials. Safety updates for high-potency transdermals in 2024 refined patient selection and risk mitigation practices. Environmental concerns are driving interest in recyclable or biodegradable materials, while product safety adheres to established biocompatibility standards. National initiatives are exploring producer responsibility programs to address healthcare waste. OTC and non-opioid patches are gaining traction in pharmacies and online platforms, supported by larger pack options and educational content.

Asia-Pacific, the fastest-growing region, benefits from rising incomes, aging demographics in countries like Japan, and improvements in retail and digital pharmacy reach. The market is projected to grow at an 8.50% CAGR through 2031, supported by strong brand presence and consumer familiarity with topical solutions. Companies like Hisamitsu leverage innovative product designs and e-commerce strategies, offering thin, mailbox-compatible packs for reliable delivery and repeat usage. Expanding healthcare access and self-care categories align with consumer preferences for targeted relief with minimal disruption to daily routines.

1. 3M
2. Abbott Laboratories
3. Bayer
4. Endo International
5. Grunenthal GmbH
6. GlaxoSmithKline
7. Hisamitsu Pharmaceutical
8. IBSA Institut Biochimique SA
9. Johnson & Johnson
10. Mentholatum Company
11. NEXGEL, Inc.
12. Novartis
13. Pfizer
14. Sanofi
15. Sorrento Therapeutics
16. Teikoku Pharma USA
17. Teva Pharmaceutical Industries
18. Topical BioMedics
19. UCB
20. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Accelerated OTC Adoption in Retail & E-Commerce Channels
  • 4.2.2 Aging Population Driving Chronic Pain Prevalence
  • 4.2.3 Regulatory Push Away from Systemic Opioids
  • 4.2.4 Technological Advances in Drug-in-Adhesive & Microneedle Patches
  • 4.2.5 Smart Patch R&D Linking Sensors with Companion Apps
  • 4.2.6 ESG-Driven Shift to Bio-Degradable Patch Substrates
• 4.3 Market Restraints
  • 4.3.1 Skin-Irritation & Adhesion Failures
  • 4.3.2 Stringent FDA / EMA Clinical-Trial Cost & Timeline
  • 4.3.3 Disposal-Related Environmental Scrutiny
  • 4.3.4 Counterfeit Patches in Low-Regulation E-Commerce
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Opioid Patches
  • 5.1.2 Non-Opioid Patches
• 5.2 By Application
  • 5.2.1 Chronic Pain
  • 5.2.2 Acute Pain
  • 5.2.3 Post-Operative Pain
  • 5.2.4 Sports & Injury-Related Pain
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Drug & Retail Pharmacies
  • 5.3.3 Online Providers
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Home-Care Settings
  • 5.4.3 Clinics & Rehabilitation Centres
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 3M Company
  • 6.3.2 Abbott Laboratories
  • 6.3.3 Bayer AG
  • 6.3.4 Endo International plc
  • 6.3.5 Grunenthal GmbH
  • 6.3.6 GSK plc
  • 6.3.7 Hisamitsu Pharmaceutical Co., Inc.
  • 6.3.8 IBSA Institut Biochimique SA
  • 6.3.9 Johnson & Johnson (Janssen)
  • 6.3.10 Mentholatum Company
  • 6.3.11 NEXGEL, Inc.
  • 6.3.12 Novartis AG
  • 6.3.13 Pfizer Inc.
  • 6.3.14 Sanofi SA
  • 6.3.15 Sorrento Therapeutics, Inc.
  • 6.3.16 Teikoku Pharma USA
  • 6.3.17 Teva Pharmaceutical Industries Ltd.
  • 6.3.18 Topical BioMedics, Inc.
  • 6.3.19 UCB Pharma
  • 6.3.20 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment